Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pyridazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | CES1 | P23141 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridazine SCHEMBL28630845 | 1.00 | FFAR3 (0.47) | FFAR3LCKFYNALDH1A1NAPRT | |
| Pyridazine SCHEMBL30071072 | 1.00 | FFAR3 (0.47) | FFAR3LCKFYNALDH1A1NAPRT | |
| Pyridazine SCHEMBL25427017 | 0.97 | FFAR3 (0.44) | FFAR3LCKFYNALDH1A1NAPRT | |
| Pyridazine SCHEMBL17962960 | 0.89 | FFAR3 (0.37) | FFAR3LCKFYNALDH1A1NAPRT | |
| Pyridazine SCHEMBL7889331 | 0.86 | CA1 (0.39) | ALDH1A1NAPRTLMNAP4HTML3MBTL1 | |
| Oxalic Acid SCHEMBL27823009 | 0.83 | NAPRT (0.36) | NAPRTLMNAP4HTML3MBTL1HCAR2 | |
| Benzene SCHEMBL10625833 | 0.82 | FFAR3 (0.70) | FFAR3LCKFYNALDH1A1NAPRT | |
| Pyridazine SCHEMBL27653386 | 0.82 | — | — | |
| Pyridazine SCHEMBL25427016 | 0.81 | CA1 (0.53) | ALDH1A1L3MBTL1TDP1 | |
| Pyridine SCHEMBL28350653 | 0.81 | NAPRT (0.45) | FFAR3LCKFYNALDH1A1NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101903382-B | Heterocyclic antiviral compounds | HOFFMANN LA ROCHE | 2012-11-28 | — | — | CN | claimed |
| CN-101903382-A | Heterocyclic antiviral compounds | HOFFMANN LA ROCHE | 2010-12-01 | — | — | CN | claimed |
| US-20250270198-A1 | PYRIDONE COMPOUNDS AS TRPA1 INHIBITORS | D. E. SHAW RESEARCH, LLC | 2025-08-28 | — | — | US | disclosed |
| US-20250154139-A1 | PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS | D. E. SHAW RESEARCH, LLC | 2025-05-15 | — | — | US | disclosed |
| EP-4519250-A1 | PYRIDONE COMPOUNDS AS TRPA1 INHIBITORS | D.E. Shaw Research, LLC (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4472624-A2 | PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS | D.E. Shaw Research, LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118973564-A | Pyridazinone compounds as TRPA1 inhibitors | D·E·萧尔研究有限责任公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023215775-A1 | PYRIDONE COMPOUNDS AS TRPA1 INHIBITORS | D. E. SHAW RESEARCH, LLC (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023150591-A2 | PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS | D.E. SHAW RESEARCH, LLC (US) | 2023-08-10 | — | — | WO | disclosed |
| US-8987312-B2 | Alpha-keto heterocycles as FAAH inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-03-24 | — | — | US | disclosed |
| WO-2013130020-A1 | QUERCETIN DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITION AND USE | ÚSTAV EXPERIMENTÁLNEJ FARMAKOLÓGIE A TOXIKOLÓGIE SAV (SK) | 2013-09-06 | — | — | WO | disclosed |
| CN-101903382-B | Heterocyclic antiviral compounds | HOFFMANN LA ROCHE | 2012-11-28 | — | — | CN | disclosed |
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-07-28 | — | — | US | disclosed |
| CN-101903382-A | Heterocyclic antiviral compounds | HOFFMANN LA ROCHE | 2010-12-01 | — | — | CN | disclosed |
| WO-2010005572-A2 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154139-A1 | PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS | TRPA1, TRPV1, TRPV5 | FFAR3 561/4885LCK 904/4885FYN 2339/4885 |
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | FAAH, FAAH2, FADS1 | FFAR3 65/4885LCK 4033/4885FYN 4056/4885 |
| US-20250270198-A1 | PYRIDONE COMPOUNDS AS TRPA1 INHIBITORS | TRPA1, TRPV1, TRPV6 | FFAR3 2892/4885LCK 1406/4885FYN 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.